CHMP recommends Cholib (Abbott HealthCare) to treat Dyslipidaemia
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Cholib 145mg/40mg and 145mg/20mg, film-coated tablets,from Abbott HealthCare Products, intended to be indicated as adjunctive therapy to diet and exercise in high cardiovascular risk adult patients with mixed dyslipidaemia to reduce triglycerides and increase HDL cholesterol levels when LDL cholesterol levels are adequately controlled with the corresponding dose of simvastatin monotherapy 20 mg or 40 mg.
The active substances of Cholib are fenofibrate/simvastatin.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins